Pelthos Therapeutics Inc. Finite-Lived Intangible Asset, Expected Amortization, Year One
Pelthos Therapeutics Inc. (PTHS) had Finite-Lived Intangible Asset, Expected Amortization, Year One of $4.18 million as of 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Notes › Goodwill and Other › Intangible Asset, Finite-Lived, and Capitalized Cost, Software to be Sold, Leased, or Marketed, Estimated Amortization Expense › Intangible Asset, Finite-Lived, after Accumulated Amortization, Estimated Amortization Expense, Fiscal Year Maturity
us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths · last filed 2026-08-13
- 2026-06-30: Finite-Lived Intangible Asset, Expected Amortization, Year One $4.18M.
- 2026-03-31: Finite-Lived Intangible Asset, Expected Amortization, Year One $4.17M.
- 2025-12-31: Finite-Lived Intangible Asset, Expected Amortization, Year One $4.17M.
| Period end | Finite-Lived Intangible Asset, Expected Amortization, Year One |
|---|---|
| 2026-06-30 | $4.18M 10-Q · filed 2026-08-13 |
| 2026-03-31 | $4.17M 10-Q/A · filed 2026-08-13 |
| 2025-12-31 | $4.17M 10-K · filed 2026-03-19 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Atara Biotherapeutics, Inc. (ATRA) | United States | $0.086B | -6.48 |
| COGNITION THERAPEUTICS INC (CGTX) | United States | $0.090B | -6.52 |
| Vaxart, Inc. (VXRT) | United States | $0.080B | 3.84 |
| Kalaris Therapeutics, Inc. (KLRS) | United States | $0.073B | -2.19 |
| Cardiff Oncology, Inc. (CRDF) | United States | $0.101B | -2.22 |
| CHAMPIONS ONCOLOGY, INC. (CSBR) | United States | $0.070B | -68.02 |
| BioStem Technologies, Inc. (BSEM) | United States | $0.069B | |
| Eloxx Pharmaceuticals, Inc. (ELOX) | United States | $0.065B | |
| Black Diamond Therapeutics, Inc. (BDTX) | United States | $0.109B | -2.48 |
| MiNK Therapeutics, Inc. (INKT) | United States | $0.063B | -5.37 |